Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Final results were consistent with previously conducted research in patients with advanced renal cell carcinoma treated with ...

Kiromic BioPharma (KRBP) reported continued efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, discusses findings from the TROPION-Breast01 study on ...

The following is a summary of “Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

For patients with previously untreated chronic lymphocytic leukemia (CLL), fixed-duration acalabrutinib-venetoclax wit ...